Wed Jun 02 2021

Dr. Vasileios Kaldis, trained as a surgeon and intensive care specialist consultant, currently heads the Emergency Department (ED) at Sismanoglio General Hospital in Athens, Greece, specifically in its northern part.

Sismanoglio General HospitalThe Sismanoglio General Hospital is a third-level facility with the capacity for 540 beds. It hires specialized medical personnel in fields such as pathology, chronic pulmonary diseases, tuberculosis, surgical chest cases, and vascular issues, but not trauma cases.

Patients entering the Emergency Department (ED) go through the established ED triage ambulatory (Fig. 3), where they receive an examination and assessment of their disease’s severity.

The hospital accepts new patients every third day from 8 am to 3 pm and operates around the clock every fourth day, during which time 300-500 patients visit the ED¹. It examines approximately 40,500 patients annually, admitting about 9,000 of them. To manage the high volume of daily tests, the central laboratory uses an automated high-throughput platform that adheres to ISO standards, processing nearly 500 orders and almost 5,000 tests daily. Most patients admitted are elderly individuals with comorbidities related to internal medicine, pulmonary, or cardiological issues, such as COPD, asthma, diabetes mellitus, CRA, heart failure, ischemic heart disease, and hypertension. These large numbers of patients place a significant strain on the medical staff, presenting numerous challenges every day.

Dr Kaldis:

Since becoming head of the Emergency Department (ED) in 2019, my mission has been to integrate innovative biomarker tools into our triage workflow for safe patient discharge. Professor Giamarellos-Bourboulis from Attikon University Hospital’s 4th Department of Internal Medicine introduced me to suPAR, thanks to the Hellenic Sepsis Group’s outstanding work, of which I’ve been a member since 2014. Last year, we launched the SUPERIOR Study protocol at Sismanoglio

Hospital in Greece General Hospital to guide antibiotic use in the ED. The Hellenic Sepsis Study Group has spearheaded ambitious clinical studies for over two decades.

Implementing suPAR can help us avoid unnecessary admissions, shorten hospital stays, save valuable time, and preserve hospital beds for those in dire need. It will particularly benefit patients categorized as Emergency Severity Index 3 (ESI3) with comorbidities in the ED.

I am optimistic that the suPAR biomarker will enhance the clinical decision-making process led by our medical staff, proving to be a crucial asset during the COVID-19 pandemic by allowing safe patient discharge, reducing hospital stays, and cutting healthcare costs. Looking forward to adopt the suPAR biomarker to improve clinical decision-making in our ED.

Vasileios Kaldis

“I believe that suPAR is the right tool to be used for assisting in discharging decisions”

– Vasileios Kaldis, MD.

1: www.sismanoglio.gr/DIATOM-TEP/DIATOM-TEP

1000+

published suPAR studies in leading medical journals

Nature Medicine Logo
Science Journal Logo
JAMA Pediatrics Logo

The suPARnostic® brand consists of 4 products:

Quick Triage

A Point of Care Solution

TurbiLatex

For Automated Systems

ELISA Assay

Clinical and Research

suPARnostic POC+

POC+

Point-of-care finger prick

New Webinar

Webinar

Catch COVID-19

-Improve your triage

Sign up to view webinar recording

View recording

suPARnostic® by ViroGates